التفاصيل البيبلوغرافية
| العنوان: |
Leveraging Real‐World Data for EMA Qualification of a Model‐Based Biomarker Tool to Optimize Type‐1 Diabetes Prevention Studies. |
| المؤلفون: |
Podichetty, Jagdeep T., Lang, Patrick, O'Doherty, Inish M., David, Sarah E., Muse, Rhoda N., Karpen, Stephen R., Song, Laura Sue, Romero, Klaus, Burton, Jackson K. |
| المصدر: |
Clinical Pharmacology & Therapeutics; May2022, Vol. 111 Issue 5, p1133-1141, 9p |
| مصطلحات موضوعية: |
AUTOANTIBODIES, TYPE 1 diabetes, BLOOD sugar measurement, GLUCOSE tolerance tests, BIOMARKERS, DIABETES |
| الشركة/الكيان: |
EUROPEAN Medicines Agency |
| مستخلص: |
The development of therapies to prevent or delay the onset of type 1 diabetes (T1D) remains challenging, and there is a lack of qualified biomarkers to identify individuals at risk of developing T1D or to quantify the time‐varying risk of conversion to a diagnosis of T1D. To address this drug development need, the T1D Consortium (i) acquired, remapped, integrated, and curated existing patient‐level data from relevant observational studies, and (ii) used a model‐based approach to evaluate the utility of islet autoantibodies (AAs) against insulin/proinsulin autoantibody, GAD65, IA‐2, and ZnT8 as biomarkers to enrich subjects for T1D prevention. The aggregated dataset was used to construct an accelerated failure time model for predicting T1D diagnosis. The model quantifies presence of islet AA permutations as statistically significant predictors of the time‐varying probability of conversion to a diagnosis of T1D. Additional sources of variability that greatly improved the accuracy of quantifying the time‐varying probability of conversion to a T1D diagnosis included baseline age, sex, blood glucose measurements from the 120‐minute timepoints of oral glucose tolerance tests, and hemoglobin A1c. The developed models represented the underlying evidence to qualify islet AAs as enrichment biomarkers through the qualification of novel methodologies for drug development pathway at the European Medicines Agency (EMA). Additionally, the models are intended as the foundation of a fully functioning end‐user tool that will allow sponsors to optimize enrichment criteria for clinical trials in T1D prevention studies. [ABSTRACT FROM AUTHOR] |
|
Copyright of Clinical Pharmacology & Therapeutics is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
